

## AN EFFICIENT SYNTHESIS OF 1 $\alpha$ ,25-DIHYDROXY VITAMIN D<sub>3</sub>

L. VANMAELE, P.J. DE CLERCQ and M. VANDEWALLE\*

State University of Ghent, Department of Organic Chemistry,  
Laboratory for Organic Synthesis,  
Krijgslaan, 281 (S.4), B-9000 GENT (Belgium)



(Received in UK 17 September 1984)

**Abstract** - An efficient synthesis of the title compound is reported based on C-1 functionalization of the triazoline Diels-Alder adduct of 25-OH previtamin D<sub>3</sub> (2c).

1 $\alpha$ ,25-Dihydroxy vitamin D<sub>3</sub> (1a) is considered as the most important and active natural metabolite of vitamin D<sub>3</sub><sup>1</sup>. Recently we have described a novel synthesis<sup>2</sup> of the 1 $\alpha$ -hydroxy vitamin D<sub>3</sub> analogue (1b), via a route essentially based on the C-1 functionalization of a previtamin D<sub>3</sub> derivative (2b) in which the unstable triene system is protected as a Diels-Alder adduct (cf. 3). We now report the application of this general plan to the synthesis of the title compound<sup>3</sup>. Treatment of crude 25-hydroxy previtamin D<sub>3</sub> (2c) (obtained upon low temperature irradiation of 25-hydroxy-7-dehydrocholesterol with a high-pressure Hg-lamp)<sup>4</sup> with phenyl-1,2,4-triazoline-3,5-dione in CH<sub>2</sub>Cl<sub>2</sub> led with complete regio- and stereoselectivity ( $\alpha$  attack) to the adduct 3 in 49 % yield. After selective protection of the 3-hydroxyl function as the *tert*-butyldimethylsilyl ether (4; 92 % yield), allylic bromination with 1,3-dibromo-5,5-dimethylhydantoin in hexane-CH<sub>2</sub>Cl<sub>2</sub> (collidine, AIBN, 20 min reflux) led with high regioselectivity to the diastereoisomeric bromides at C-1 (crude yield > 80 %). Immediate oxidation of the allylic bromides with bis-tetrabutyl-ammoniumdichromate<sup>5</sup> in CHCl<sub>3</sub> (reflux, 3 h) led to enone 5 in 56 % overall yield (from 4) after column chromatography on silica gel. This two-step C-1 functionalization is a modification superior to the three-step procedure previously described, for the synthesis of the 1 $\alpha$ -hydroxy vitamin D<sub>3</sub> analogue<sup>2</sup> (1b). After cleavage of the silyl ether in 5 (n-butyric acid, (n.Bu)<sub>4</sub>NF, THF, 2 h, 20°C; 84 % yield), the reduction of 6 with aluminumhydride in THF at -70°C afforded with high stereoselectivity the triol 7 (yield 87 % after HPLC purification). The stereochemical result is rationalized by an intramolecular hydride transfer after reaction of the reducing agent with the 3-hydroxyl group. Deprotection of the 6,8-diene system upon refluxing 7 at 85°C in carefully degassed methanol - 15 N KOH under Ar for 70 h afforded after HPLC purification 1(S),25-dihydroxy vitamin D<sub>3</sub> (1a) next to 1(S),25-dihydroxy previtamin D<sub>3</sub> (2a) in a 5.7:1 ratio (61 % yield). The assignment of the 1(S)-configuration in diols 1a, 2a and 7 follows from the analysis of the <sup>1</sup>H NMR spectral data obtained for the previtamin derivative 2a, which showed patterns for H-1 and H-3, i.e., broad

signal at 4.20 ppm ( $W\ 1/2 = 9.5$  Hz), multiplet at 4.06 ppm ( $\Sigma J = 27.5$  Hz), almost identical to those obtained for the *trans*-diol 2b<sup>6,7</sup>, i.e., broad signal at 4.20 ( $W\ 1/2 = 9.0$  Hz), multiplet at 4.05 ( $\Sigma J = 28.0$  Hz); the corresponding *cis*-diol (1-*epi*-2b)<sup>6</sup>, however, shows resonances at 4.02 (broad signal,  $W\ 1/2 = 10.0$  Hz) and 4.24 (multiplet,  $\Sigma J = 14.5$  Hz).

Heating of 2a for 2 h at 70°C in order to establish equilibration gave 1a which after crystallization from benzene-ethyl acetate (m.p. 95-96°C) showed spectral properties in accord with previous reports (UV, <sup>1</sup>H NMR)<sup>3d</sup>. The overall yield of crystalline 1a starting from the adduct 3 is 20 %.



#### EXPERIMENTAL SECTION

The m.ps. are uncorrected. IR spectra were recorded on a Beckman IR 4230 spectrophotometer, UV spectra on a Unicam SP 1750 ultraviolet spectrophotometer and mass spectra on a AEI MS-50 spectrometer. The <sup>1</sup>H NMR spectra were recorded at 360 MHz (WH-Brucker) in CDCl<sub>3</sub> with TMS as internal standard. Chemical shifts ( $\delta$ ) are expressed in ppm. R<sub>f</sub> values are quoted for Merck silica gel 60 GF<sub>254</sub> TLC plates of thickness 0.25 mm. HPLC separations were performed on silica gel, on a Prep LC/System 500 (Waters) apparatus or on a Model 6000 A Solvent Delivery System HPLC (Waters).

#### The adduct 3

To a soln of crude 2c (19.0 g) obtained upon low temperature irradiation of 25-hydroxy-7-dehydrocholesterol in dry CH<sub>2</sub>Cl<sub>2</sub> (300 mL) is added dropwise at 10°C a soln of 4-phenyl-1,2,4-triazoline-3,5-dione (8.6 g; 49.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL). After concentration in vacuo the residue is dissolved in acetone (60 mL) and cooled to -20°C. After separation of crystalline 3 (6.9 g), the mother liquor is purified by column chromatography affording another 6.7 g of 3. Total yield 49 %, calculated on consumed 25-hydroxy-7-dehydrocholesterol. R<sub>f</sub> (hexane/acetone, 7:3) : 0.16; UV (CH<sub>3</sub>OH) :  $\lambda_{\max}$  216 nm; IR (KBr) : 3420, 2960, 2930, 2860, 1760, 1700, 1600, 1500, 1410, 760, 680, 635 cm<sup>-1</sup>; <sup>1</sup>H NMR : 0.78 (s, 3H), 0.94

(d, J = 5.5 Hz, 3H), 1.22 (s, 6H), 1.80 (s, 3H), 3.99 (m, 1H), 4.46 (m, 1H), 5.15 (m, 1H), 5.35 (m, 1H), 7.31-7.49 (m, 5H); MS : m/z 575 (M<sup>+</sup>, 2), 557 (1.5), 59 (100).

#### The silyl ether 4

A soln of adduct 3 (1 g; 1.74 mmol), imidazole (295 mg; 4.35 mmol) and *tert*-butyldimethylsilyl chloride (367 mg; 2.44 mmol) in DMF (20 mL) is stirred under argon at 25°C for 5 h. After addition of an equal volume of hexane stirring is continued for 10 min. After addition of satd NaCl soln (2 mL) and extraction with hexane (4 x 10 mL), the combined organic phases are washed with 5 % HCl soln (5 mL), satd NaHCO<sub>3</sub> soln (5 mL) and brine (2 x 5 mL). The oil obtained after drying over MgSO<sub>4</sub> and concentration is treated with CH<sub>3</sub>CN. Separation of crystalline 4 and purification of the mother liquor by column chromatography (hexane/acetone, 9:1) affords 4 (1.101 g; 92 % yield). M.p. = 153°C (CH<sub>3</sub>CN); R<sub>f</sub> (hexane/acetone, 4:1) = 0.28; UV (CH<sub>3</sub>OH) :  $\lambda_{\max}$  = 216 nm; IR (KBr) : 3400, 3020, 2950, 2860, 1770, 1715, 1600, 1540, 1420, 1380, 1220, 860, 840, 690, 670 cm<sup>-1</sup>; <sup>1</sup>H NMR : 0.05 (2 x s, 6H), 0.79 (s, 3H), 0.88 (s, 9H), 0.94 (d, J = 5.5 Hz, 3H), 1.22 (s, 6H), 1.77 (s, 3H), 3.75 (m, 1H), 4.47 (m, 1H), 5.17 (m, 1H), 5.30 (m, 1H), 7.30-7.51 (m, 5H); MS : m/z 689 (M<sup>+</sup>, < 1), 671 (5), 75 (100).

#### The enone 5

To a soln of 4 (0.564 g; 0.819 mmol) in dry hexane (9 mL) and CH<sub>2</sub>Cl<sub>2</sub> (1.3 mL) at reflux is added collidine (108  $\mu$ L, 0.819 mmol), AIBN and dimethyldibromohydantoin (234 mg; 0.819 mmol). After 20 min the cooled suspension is filtered over celite and washed with hexane (20 mL) and CHCl<sub>3</sub> (10 mL). The residual oil, obtained after concentration, is dissolved in dry CHCl<sub>3</sub> (6 mL) and treated with bis-tetrabutylammoniumdichromate (3.2 g; 4.59 mmol). After reflux for 3 h the cooled suspension is filtered over silica gel (20 g) and eluted with ether (400 mL). Concentration and purification by column chromatography (hexane/acetone, 85:15) affords 5 (320 mg; 56 % yield). R<sub>f</sub> (hexane/acetone, 7:3) = 0.39; UV (CH<sub>3</sub>OH) :  $\lambda_{\max}$  = 222 nm; IR (KBr) : 3500, 2960, 2930, 2860, 1770, 1715, 1670, 1630, 1500, 1410, 1375, 1260, 1100, 870, 840, 760, 640 cm<sup>-1</sup>; <sup>1</sup>H NMR : 0.04 (2 x s, 6H), 0.79 (s, 3H), 0.88 (s, 9H), 0.95 (d, J = 5 Hz, 3H), 1.22 (s, 6H), 1.91 (s, 3H), 2.49 (dd, J = 12.16 Hz, 1H), 2.72 (dd, J = 4.16 Hz, 1H), 3.98 (m, 1H), 4.54 (m, 1H), 5.15 (m, 1H), 5.37 (m, 1H), 7.31-7.51 (m, 5H); MS : m/z 207 (22), 75 (100).

#### The enone 6

To a soln of enone 5 (409 mg; 0.582 mmol) and butyric acid (0.266 mL; 2.909 mmol) in dry THF (5 mL) under argon is added dropwise a soln of tetrabutylammonium fluoride (5.818 mL of a 1 M soln) in THF. After stirring for 2 h at 20°C the mixture is treated with ether (40 mL) and washed with 5 % HCl soln (5 mL), satd NaHCO<sub>3</sub> soln (2 x 5 mL) and brine (5 mL). After drying (MgSO<sub>4</sub>) and concentration the residue is purified by column chromatography (hexane/acetone, 3:2) affording 6 (288 mg; 84 % yield). R<sub>f</sub> (hexane/acetone, 3:2) = 0.30; UV (CH<sub>3</sub>OH) :  $\lambda_{\max}$  = 223 nm; IR (KBr) : 3420, 2960, 2930, 2860, 1765, 1705, 1665, 1625, 1600, 1500, 1415, 1380, 1360, 1260, 1230, 1160, 1140, 1105, 1090, 1050, 940, 910, 760, 740, 690, 635 cm<sup>-1</sup>; <sup>1</sup>H NMR : 0.79 (s, 3H), 0.94 (d, J = 5 Hz, 3H), 1.22 (s, 6H), 1.95 (s, 3H), 4.23 (m, 1H), 4.53 (m, 1H), 5.15 (m, 1H), 5.41 (m, 1H), 7.31-7.49 (m, 5H); MS : m/z 396 (10), 394 (25), 59 (100).

#### The diol 7

To a suspension of LiAlH<sub>4</sub> (132 mg; 3.438 mmol) in dry THF (10 mL) is added dropwise at 25°C a soln of AlCl<sub>3</sub> (152 mg; 1.146 mmol) in dry THF (4 mL). After stirring vigorously for 10 min 3.24 mL of the above soln is added cautiously to a cooled (-70°C) soln of enone 6 (125 mg; 0.2122 mmol) in dry THF (1 mL). After stirring for 1 h at -60°C a soln of 5 % HCl/THF (1:1; 5 mL) is added dropwise and the resulting suspension brought to 25°C. After the addition of ether (40 mL) and CH<sub>2</sub>Cl<sub>2</sub> (10 mL) the suspension is stirred vigorously for 5 min. The aqueous phase is extracted with ether (3 x 15 mL) and the combined organic phases washed with 5 % HCl (15 mL), satd NaHCO<sub>3</sub> (15 mL) and brine (2 x 10 mL). After drying and concentration in vacuo the residue is purified by HPLC (benzene/acetone, 7:3) affording 7 (91 mg; 73 % yield). R<sub>f</sub> (benzene/acetone, 7:3) = 0.14; UV (CH<sub>3</sub>OH) :  $\lambda_{\max}$  = 215 nm; IR (KBr) : 3400, 2960, 2930, 2860, 1770, 1710, 1600, 1500, 1420, 1375, 1270, 1235, 1150, 1110, 1045, 910, 760, 710, 690, 640 cm<sup>-1</sup>; <sup>1</sup>H NMR : 0.78 (s, 3H), 0.94 (d, J = 5.5 Hz, 3H), 1.22 (s, 6H), 1.93 (s, 3H), 4.09 (m, 1H), 4.27 (m, 1H), 4.47 (m, 1H), 5.19 (m, 1H), 5.29 (m, 1H), 7.31-7.49 (m, 5H).

#### 1(S)-25-dihydroxyvitamin D<sub>3</sub> (1a)

A degassed soln of diol 7 (140 mg; 0.237 mmol) and of KOH in aqueous MeOH (8.4 mL of a soln of 112 g KOH in 84 mL H<sub>2</sub>O-MeOH, 1:1) is stirred under argon at 85°C for 70 h. The MeOH is removed in vacuo and the aqueous phase extracted with ether. The combined organic phases are washed with 10 % KOH soln (5 mL), 5 % HCl soln (2 x 10 mL), satd NaHCO<sub>3</sub> soln (5 mL) and brine (8 mL). After drying (MgSO<sub>4</sub>) and concentration the residue is purified by HPLC (hexane/acetone, 7:3) affording 51 mg of 1(S),25-dihydroxy vitamin D<sub>3</sub> (1a) and 9 mg of 1(S),25-dihydroxy previ-

tamin D<sub>3</sub> (2a); total yield 61 %. 1a : m.p. = 95-96°C (benzene/ethyl acetate); R<sub>f</sub> (hexane/acetone, 7:3) = 0.13; UV (CH<sub>3</sub>OH) =  $\lambda_{\text{max}}$  = 266 nm; IR (KBr) : 3350, 2940, 2860, 1690, 1630, 1470, 1375, 1360, 1210, 1145, 1050, 960, 910, 800, 740 cm<sup>-1</sup>; <sup>1</sup>H NMR : 0.55 (s, 3H), 0.94 (d, J = 6.5 Hz, 3H), 1.22 (s, 6H), 4.23 (m, 1H,  $\Delta J$  = 20.0 Hz), 4.43 (m, 1H,  $\Delta J$  = 12.0 Hz), 5.00 (m, 1H), 5.33 (m, 1H), 6.02 (d, J = 11 Hz, 1H), 6.38 (d, J = 11 Hz, 1H). 2a : R<sub>f</sub> (hexane/acetone, 7:3) = 0.13; UV (CH<sub>3</sub>OH) :  $\lambda_{\text{max}}$  = 260 nm; <sup>1</sup>H NMR : 0.71 (s, 3H), 0.96 (d, J = 6.5 Hz, 3H), 1.23 (s, 6H), 1.77 (s, 3H), 4.06 (m, 1H), 4.20 (m, 1H), 5.51 (m, 1H), 5.79 (d, J = 12 Hz, 1H), 5.91 (d, J = 12 Hz, 1H).

**Acknowledgement** - The "Nationaal Fonds voor Wetenschappelijk Onderzoek" and the "Ministerie voor Wetenschapsbeleid" are gratefully acknowledged for financial support to the laboratory. We thank Dr. Halkes of Duphar B.V. for providing the starting material.

## References

1. Vitamin D. Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism. Ed. A.W. Norman, K. Schaefer, D.v. Herrath and H.G. Grigoleit in W. De Gruyter Berlin - New York, 1982.
2. L.J. Vanmaele, P.J. De Clercq and M. Vandewalle, *Tetrahedron Lett.* 995 (1982).
3. For other syntheses, see : (a) E.J. Semmler, M.F. Holick, H.K. Schnoes and H.F. DeLuca; *Tetrah. Lett.*, 4147 (1972); (b) D.H.R. Barton, R.H. Hesse, M.M. Pechet and E. Rizzardo; *J.C.S. Chem. Comm.* 203 (1974); (c) Z. Cohen, E. Keinan, Y. Mazur and A. Ulman, *J. Org. Chem.*, **41**, 2651 (1976); (d) T. Sato, H. Yamauchi, Y. Ogata, M. Tsujii, T. Kunii, K. Kagei, S. Toyoshima, T. Kobayashi, *Chem. Pharm. Bull.*, **26**, 2933 (1978). For a general review, see : B. Lythgoe, *Chem. Soc. Rev.*, **9**, 449 (1980).
4. S.J. Halkes and N.P. Van Vliet, *Rec. Trav. Chim. Pays-Bas*, **88**, 1080 (1969).
5. F. Rolla and D. Landini; *Chem. & Ind.*, 213 (1979).
6. L.J. Vanmaele, P.J. De Clercq, M. Vandewalle, S.J. Halkes, W.R.M. Overbeek, *Tetrahedron*, **40**, 1179 (1984).
7. Absolute proof of the 1(S)-configuration in 1 $\alpha$ -hydroxyvitamin D<sub>3</sub> (1b) and hence 2b was obtained by comparison with an authentic sample (see ref. 2).